Afficher la couverture 'Expanding biomarkers for PARP inhibitors | Coussy, Florence' en grand format
/5

0 avis

Expanding biomarkers for PARP inhibitors

Archive ouverte

Coussy, Florence | Bidard, François Clément

Edité par CCSD ; Nature Research -

International audience. The efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as targets for PARP inhibitors in breast cancer, whereas the added predictive value of HR signatures remains uncertain.

Consulter en ligne

Suggestions

Du même auteur

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

Archive ouverte | ter Brugge, Petra | CCSD

International audience. The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing met...

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Archive ouverte | Hatem, Rana | CCSD

Triple-negative breast cancers (TNBC) are characterized by frequent alterations in the PI3K/AKT/mTOR signaling pathway. In this study, we analyzed PI3K pathway activation in 67 patient-derived xenografts (PDX) of breast cancer and...

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Archive ouverte | Coussy, Florence | CCSD

Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR). Triple-negative breast cancer (TNBC) could be eli...

Chargement des enrichissements...